Liu H, et al. - This study assessed the oncogenic mechanism of Golgi phosphoprotein 3 (GOLPH3) and to see if it can be used as a novel biomarker and therapeutic strategy for patients with hepatocellular carcinoma (HCC). By activating mTOR signaling pathway, GOLPH3 contributed to the HCC tumorigenesis. It was observed that GOLPH3 was a promising biomarker and therapeutic target for HCC. This investigation could provide a basis for developing effective approaches to treat HCC patients with GOLPH3 overexpression.